AbbVie Announces Topline Results From Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine For High Folate Receptor-Alpha Expressing Platinum-Sensitive Ovarian Cancer; PICCOLO Met Its Primary Endpoint With An ORR Of 51.9%; The Median DOR, A Key Secondary Endpoint, Was 8.25 Months
Portfolio Pulse from Benzinga Newsdesk
AbbVie announced positive topline results from its Phase 2 PICCOLO trial evaluating mirvetuximab soravtansine for high folate receptor-alpha expressing platinum-sensitive ovarian cancer. The trial met its primary endpoint with an ORR of 51.9% and a median DOR of 8.25 months. No new safety concerns were identified.
June 06, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie announced positive results from its Phase 2 PICCOLO trial for mirvetuximab soravtansine in ovarian cancer, achieving a 51.9% ORR and 8.25 months median DOR. No new safety concerns were identified.
The positive results from the Phase 2 PICCOLO trial are likely to boost investor confidence in AbbVie's oncology pipeline, potentially driving the stock price up in the short term. The achievement of the primary endpoint and the absence of new safety concerns are significant positive factors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100